AptarGroup : Bank of America 2026 Global Agriculture and Materials Conference

About this update from Aptargroup, Inc.

Stephan Tanda President and CEO Mary Skafidas SVP, Investor Relations & Communications Bank of America 2026 Global Agriculture and Materials Conference February 25, 2026 1 Aptar is a Global Leader in Drug and Consumer Product Dosing, Dispensing and Protection Technologies 2025 % of Total Reported Sales Beverage 5% Food We combine product design, engineering and science to create core differentiating technologies. 69% Pharma % of Total FY 2025 Adj EBITDA 1 Proprietary drug delivery systems provide a competitive edge, Home Care 3% Personal 10% Closures 19% Pharma 2 Proprietary Drug Delivery Systems 3 33% driven by a strong innovation pipeline and over 7,000 active and pending patents in our portfolio. Each segment has attractive growth potential. Consistently recognized as a sustainability leader. Robust balance sheet providing ample opportunity to deploy Care 16% Fragrance, Facial Beauty 35% $3.8B 46% Injectables 8% firepower - 1-3x leverage corridor long-term target. 13% Closures % of Total FY 2025 Adj EBITDA 1 18% Beauty % of Total FY 2025 Adj EBITDA 1 Over the last five years, we have returned about $1.2B to shareholders through dividends and share repurchases. Skincare and Color Cosmetics 20% Active Material Science Solutions 5% 1: Adjusted EBITDA - See Appendix for definition. 2: 2025 Annual Revenue. 3: Proprietary Drug Delivery Devices includes Prescription, Consumer Healthcare and Digital health Markets. 3 Technologies and Industrial Capabilities Deployed Across End Markets In Place Developing Proprietary Technology Platforms 1 Industrial Capabilities Dispensing Fine Mist Pumps Dispensing Closures Dispensing Lotion Pumps Active Materials Elastomeric Components Airless Systems Aerosol Valves & Bag-On-Valves Services Digital + Connected Devices Precision Injection Molding High Speed Assembly, AI QC 2 Metal Stamping & Anodizing Decoration Pharma Beauty Personal Care Home Care Beverage Food Sustainable Solutions Industry Leading Innovation, Unmatched Reliability Closures 16% 22% 7,300+ Patents (granted or pending) 62% Consistent Patent Investments 1 Beauty Pharma Our advanced dispensing and dosing solutions are intended to maximize user satisfaction, delivering superior value to both customers and end users. R&D spend as a percentage of sales for Aptar is ~3% 3 with a larger portion of the R&D spend going to Pharma Proprietary Intellectual Property Aptar designs and owns its IP Pharmaceutical Excellence Aptar meets ISO 5, 6, 7, 8, and 9 cleanroom standards, with clean rooms in every facility to help ensure product integrity and safety Regulatory Expertise and High Reliability Aptar supports emergency medicines with demonstrated reliability of 99.999% 2 . Regulatory know-how makes us a key partner, accelerating success from strategy to commercialization Advanced Dispensing Solutions Aptar's proprietary technologies deliver high-performance dispensing, enhancing patient and consumer experiences Innovation & Rapid Development Integrated labs and prototyping accelerate efficient solution design Human Factors Expertise We embed human factors into design to help ensure safety, usability, and a superior user experience 1: Granted and pending as of April 2025 based on company research and publicly available information 2. As demonstrated in NDA filings using our dispensing systems for emergency situations 3: For fiscal year 2025. 5 Well-Positioned for Long-Term Revenue Growth Beauty $38B Pharma $165B Closures $7B Closures ~2% Beauty ~4% Pharma ~7% Aptar plays in large and growing TAMs Projections for market growth support long-term revenue growth Focused execution and driving the right investment mix expected to drive revenue growth at or above the market Highly diversified model, with no single product or geography driving long-term growth Total Addressable Market Across Aptar's Growing End Markets 1 Long-Term Market Projected Growth Rates Prioritizing Capital Deployment for Highest Returns We remain focused on selective and disciplined capital allocation Repurchases - $0.9B Dividends - $0.9B 17% 17% 66% CapEx & Acquisitions - $3.5B Pharma ~50% Profitable organic growth powered by disciplined capital allocation Continued emphasis on strategic acquisitions and high-value partnerships Consistent return of shareholder value through dividends and share repurchases ~Two-thirds of capital reinvested into core business operations and growth initiatives $1.2B Returned to shareholders through dividends and share repurchases over the last five years ~One-third of capital returned to shareholders 2017 - 2025 Recent Recognitions Our award-winning commitment to sustainability is a competitive advantage that drives impact for our customers CDP Climate A List Newsweek In the Top 100 2024-2025 Companies Women Companies Leader 2021 - 2025 from 2019-2025 from 2020-2024 2023-2025 in France 2020-2026 from 2021-2025 2024-2025 2020-2024 2020-2023 America's Most Responsible Forbes One of the World's Top Companies For TIME One of the World's Most Sustainable CDP Recognized as a Supplier Engagement EcoVadis Sustainability Rating Platinum Top 1% Barron's* In the Top 100 Most Sustainable Companies ISS ESG Achieved Prime Status USA Today One of America's Climate Leaders Le Point One of the Most Responsible Companies *Used with permission. ©2025 Dow Jones & Company, Inc. 8 Aptar Pharma Aptar Pharma - At a Glance FY 2025 % of Pharma Segment Sales Active Material Science Solutions 10% Injectable Solutions & Components Proprietary Drug Delivery Systems 1 19% $1.7B in Revenue 71% We are a proprietary leader in precision drug dosing and dispensing active in highly regulated markets IP Breadth Diversified Portfolio Conversion: Originator → Generic Transition → OTC Regulatory expertise makes us a trusted partner Our services help enable early engagement Our digital health offerings set us apart from other suppliers A strong balance sheet supports pharma investment and long-term strength FY 2025 Core Sales Growth % 2 3% Adjusted EBITDA Margin % 2 35.0% % of Total Revenue 46% % of Total Adjusted EBITDA 2 69% 1: Proprietary Drug Delivery Devices includes Prescription, Consumer Healthcare and Digital health Markets. Strong Market Position Fortified by Differentiated Position Aptar Pharma's Strengths Increasing Regulatory Complexity Proven track record in supporting approval of combination products (molecule + delivery system) in US and EU. Our experts work collaboratively with regulatory agencies to address new product specific guidance. Significant Engineering & Scientific Know-How Strong IP Portfolio, bolstered by decades of expertise. Our scientific affairs teams are building an understanding of pathway modeling. Quality & Reliability Proven reliability. Multiple market references with a proven regulatory track record. Long-Standing Customer and Partner Relationships 30+ years of experience. Established lines eliminates capacity reservation. Capital Intensity Global footprint -- Significant investment in manufacturing capacity has improved our ability to meet customer needs and market demands. Total Drug Sales by Delivery Route Dermal / Transdermal Well positioned with proprietary products Technology platform shared with Beauty segment Respiratory 2% Eye Care Well positioned with proprietary products Other Routes Well positioned with proprietary products 5% 4% 1% 43% $1.7T Total Drug Sales Market 1 45% Oral Strong growth potential Focused on specialized high-value market for drugs with sensitive formulations Injectables Growing position with expanded capacity in High-Value Product offerings Aptar Pharma: Global Reach, Trusted Partner, Broad Offerings $2,000 Reported Net Sales (in Millions $) $700 Adjusted EBITDA (in Millions $) $1,800 $1,600 $1,400 $600 $500 $1,200 $1,000 $800 $400 $300 $600 $400 $200 $- 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 $200 $100 $- 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 FY 2025 Net Sales Reported Net Sales Growth % Adjusted EBITDA 1 Adjusted EBITDA Margin % 1 $1.7B 6% $608M 35.0% 1: See Appendix for definitions. 13 Prescription Drug Therapeutic Areas For Respiratory, Injectable, Ophthalmic, and Dermal Drug Delivery Routes Top Therapeutic Areas by Average Weighted Value of Opportunities in Pipeline (As of September 30, 2025) Respiratory Biologics (Inj.) Systemic Nasal Drug Delivery o Central nervous system (CNS), Pain management, Emergency medicine Small Molecule (Inj.) Ophthalmology Allergic Rhinitis Vaccines (Inj. and Nasal) Dermatology Key Takeaways Diverse therapeutic areas support a well-diversified portfolio Injectables have taken an increasingly prominent role in the pipeline As systemic nasal drug delivery expanded, nasally delivered CNS therapies represented the majority of opportunities Historically, the pipeline contributes about 10% of annual revenue, while 90% is driven by repeat business* Our core business continues to deliver-systemic nasal delivery is accelerating, and Injectables now accounts for a greater portion of the pipeline Pharma's primary growth driver has been volume growth and favorable mix shift within repeat business Deep-dive of Proprietary Drug Delivery Systems Pipeline Metabolism Obesity Diabetes Musculoskeletal Muscular Dystrophy Creatine Deficiency ALS Vaccine & Antiviral COVID-19 RSV Influenza Universal Flu mAbs / mRNA Cardiovascular Molecules Neurological Disorders Autism Spectrum Sleep Disorders Prader-Willi Neurodegeneration Alzheimer's Dementia Parkinson's Huntington Multiple Sclerosis Aging Eye Diseases Dry Eye Glaucoma Mental Health Stroke / Heart Failure Cardiac Arrhythmia Edema and Tachycardia (Just Approved) ADHD PTSD / Anxiety Schizophrenia Depression Addiction Bipolar Disorders Oncology Glioblastoma Breast Cancer Brain Cancer Meningioma Traumatic Injury Traumatic Brain Injury Newborn Brain Damage Spinal Cord Injury Lifecycle of a Nasally Delivered Molecule Using Aptar's Proprietary Drug Delivery System Development 1988 Originator 1994 Generics 2006 Brand Extension 2007 Originator Goes OTC Status 2014 Generics Go OTC 2017 Drug X first approved for prescription in 1994 with Aptar's nasal delivery system (1 st generation) in its Drug Master File (DMF) Using Aptar's Delivery technology remains the delivery system (with improvements, IP, etc.) throughout the lifecycle of the drug More than 3 billion Aptar delivery systems have been sold for this molecule Aptar has received revenue for its respective delivery systems for this molecule for 30 years and counting Revenue from Drug X 30x in revenue One molecule can create sustained revenue Pipeline launches add to steady stream of revenue from growing repeat business 1 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Originator Generic OTC Added Early-Stage and Late-Stage Capabilities to Bolster Core Business Discovery Clinical Trial Development Market Launch and LCM Discovery and Pre-Clinical From Phase I to Phase III Commercial Phase IV and LCM Services support, accelerate and derisk our customers' product development and enhance patients' experiences From NDAs to ANDAs and 505b2 filings, our regulatory expertise and Historical positioning credibility help derisk pharma company's submissions by leveraging 30+ years of experience supporting our customers and responding to regulators API Device C Formulation Patient Insight Analytical testing Human Factors Clinical supplies Regulatory support Clinical Manufacturing Commercial Manufacturing C Release Patient onboarding Device supply-patient monitoring solutions Design fo rmulation d Device G ev. Clinical trials Regulatory fillings Manufacturing Market launch G post-launch Adding Value Throughout the Drug Development Process Pharma Full Year 2025 Results $2,000 $1,800 $1,600 $1,400 $1,200 $1,000 $800 $600 $400 $200 $- FY 2025 Sales $1,737 $1,643 Reported 6% Core 3% Acquisitions 0% Currency Effects 3% (in millions $) FY 2024 FY 2025 40% 30% 20% 10% 0% Adjusted EBITDA Margin % 1 34.6% 35.0% FY 2024 FY 2025 Full Year 2025 Reported sales grew 6% to $1.74B, core sales up 3% as strong volume and higher royalties offset lower tooling sales and pricing adjustments. Prescription drug delivery core sales up 5%, driven by higher demand for emergency medicine and CNS solutions, plus increased royalty revenue, even with the destocking of Naloxone delivery systems in the fourth quarter. Consumer healthcare core sales down 8%, however the segment returned to growth after a period of inventory management in the cold and cough space. Growth in eye care solutions remained strong. Injectables core sales up 11% on strong GLP-1 component demand; active material science core sales up 3% as higher film/diabetes solution demand outweighed last year's large tooling sale. Aptar Beauty Aptar Beauty: At a Glance FY 2025 % of Beauty Segment Sales Sales By Region (FY 2025 by Ship To Destination) 18% 61% 9% 12% Home Care 5% Fragrance, Facial Skincare and Color Cosmetics 37% $1.3B in revenue 58% Personal Care A significant amount of Europe sales end up in Asia and U.S. FY 2025 Core Sales Growth % 1 2% Adjusted EBITDA Margin % 1 12.1% % of Total Revenue 35% % of Total Adjusted EBITDA 1 18% 1 Attention : This is an excerpt of the original content. To continue reading it, access the original document here .

View stock analysis, news, and events for Aptargroup, Inc.